Britecyte’s research project “A Mesenchymal Stem Cell Containing Matrix for Nonalcoholic Steatohepatitis (NASH)” was awarded a $270,000 Commercialization Program Grant from the Maryland Stem Cell Research Fund (MSCRF).
The award supported early commercialization work advancing Britecyte’s adipose-based regenerative medicine platform.